BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424 | -11.7% | 16,095 | -42.3% | 0.03% | -15.8% |
| Q2 2023 | $480 | +90.5% | 27,916 | +83.5% | 0.04% | +111.1% |
| Q1 2023 | $252 | -2.3% | 15,216 | -55.0% | 0.02% | -14.3% |
| Q4 2022 | $258 | -99.9% | 33,826 | +1.4% | 0.02% | -32.3% |
| Q3 2022 | $331,000 | -29.9% | 33,350 | -35.8% | 0.03% | -27.9% |
| Q2 2022 | $472,000 | +48.9% | 51,948 | +66.2% | 0.04% | +330.0% |
| Q1 2022 | $317,000 | – | 31,264 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |